Business
In this episode of Denatured, you’ll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. We’ll discuss next-generation obesity solutions tackling GLP-1’s muscle loss and adherence challenges, through innovative muscle preservation, oral administration and combination therapy.
FEATURED STORIES
An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
2021 is off to a hopeful start for some companies, executives and scientists, while others are forced to fold programs and recalibrate.
Sosei Group Corporation has announced it is regaining the worldwide rights to its muscarinic agonist programs after AbbVie said it is backing away from the program.
Draper, a not-for-profit research and development organization, is speeding the process with new tools designed specifically to produce cell therapies at scale.
The new process development and manufacturing facility will focus on viral vectors and advanced therapies. It is the third location for Diosynth’s CDMO viral vector services.
In the first week of the new year, two companies raised more than $150 million in separate Series A financing rounds to fund research programs aimed at developing treatments for cancer and rare diseases.
With the new year comes a changing of the guard at Pfizer. After two years of helming the company’s pharma operations, Chief Medical Officer Mace Rothenberg announced his departure from Pfizer on social media.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 5, 2021.
Dr. Lynn Seely bows out as Myovant pivots to commercialize new drug.
Calithera Biosciences reported that its CANTATA clinical trial of telaglenastat in patients with advanced or metastatic renal cell carcinoma (RCC) failed to hit the primary endpoint.